Related Experiment Video
Updated: Oct 12, 2025

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
Published on: July 25, 2013
Deep learning approaches for de novo drug design: An overview
Mingyang Wang1, Zhe Wang1, Huiyong Sun2
1Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, PR China.
Abstract:
De novo drug design is the process of generating novel lead compounds with desirable pharmacological and physiochemical properties. The application of deep learning (DL) in de novo drug design has become a hot topic, and many DL-based approaches have been developed for molecular generation tasks. Generally, these approaches were developed as per four frameworks: recurrent neural networks; encoder-decoder; reinforcement learning; and generative adversarial networks. In this review, we first introduced the molecular representation and assessment metrics used in DL-based de novo drug design. Then, we summarized the features of each architecture. Finally, the potential challenges and future directions of DL-based molecular generation were prospected.
More Related Videos
Related Concept Videos
Drug Discovery: Overview
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Preclinical Development: Overview
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Pharmacodynamics: Overview and Principles
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

